Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-004464-26 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A (single ascending dose) Dose A1 | Experimental | Single dose A1 of ACT-777991. |
|
| Part A (single ascending dose arm) Dose A2 | Experimental | Single dose A2 of ACT-777991. |
|
| Part A (single ascending dose arm) Dose A3 | Experimental | Single dose A3 of ACT-777991. |
|
| Part A (single ascending dose arm) Dose A4 | Experimental | Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days. |
|
| Part A (single ascending dose arm) Dose A5 | Experimental | Single dose A5 of ACT-777991. |
|
| Part A (single ascending dose arm) Dose A6 |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ACT-777991 (SAD) | Drug | ACT-777991 administered as hard capsules for oral use. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of treatment-emergent adverse events. | From first dose on Day 1 to Day 4 after the last dose was administered |
| Measure | Description | Time Frame |
|---|---|---|
| All cohorts: Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-777991 | Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered | |
| All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf) of ACT-777991 |
Not provided
General Inclusion Criteria:
Inclusion Criteria for Part B:
General Exclusion Criteria:
Exclusion Criteria for the absorption,distribution, metabolism and excretion (ADME) evaluation:
Exclusion Criteria for Part B:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Trials | Idorsia Pharmaceuticals Ltd. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| QPS Netherlands B.V. | Groningen | 9713 GZ | Netherlands |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Single-center, double-blind, randomized, placebo-controlled Phase 1 study
Not provided
Not provided
Not provided
| Experimental |
Single dose A6 of ACT-777991. |
|
| Part A (single ascending dose arm) Dose A7 | Experimental | Single dose A7 of ACT-777991. |
|
| Part A (single ascending dose arm) Dose A8 | Experimental | Single dose A8 of ACT-777991. |
|
| Part B (multiple ascending dose) Dose B1 | Experimental | Multiple doses B1 of ACT-777991. |
|
| Part B (multiple ascending dose) Dose B2 | Experimental | Multiple doses B2 of ACT-777991. |
|
| Part B (multiple ascending dose) Dose B3 | Experimental | Multiple doses B3 of ACT-777991. |
|
| Part B (multiple ascending dose) Dose B4 | Experimental | Multiple doses B4 of ACT-777991. |
|
| Part B (multiple ascending dose) Dose B5 | Experimental | Multiple doses B5 of ACT-777991. |
|
| Part A (single ascending dose) Absolute Bioavailability | Experimental | Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8. |
|
| Part B (multiple ascending dose) ADME | Experimental | Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5. |
|
| ACT-777991 (MAD) | Drug | ACT-777991 administered as hard capsules for oral use, once daily. |
|
| Placebo (SAD) | Drug | ACT-777991 matching placebo administered as hard capsules for oral use. |
|
| Placebo (MAD) | Drug | Matching placebo administered as hard capsules for oral use, once daily. |
|
| 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability) | Drug | Single dose of 14C-ACT-777991 microtracer, administered intravenously. |
|
| Microtracer matching placebo (SAD - Absolute Bioavailability) | Drug | Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously. |
|
| 14C-ACT-777991 microtracer (MAD - ADME) | Drug | Single dose of 14C-ACT-777991 microtracer, oral solution.. |
|
| Microtracer matching placebo (MAD - ADME) | Drug | Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution. |
|
| Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered |
| All cohorts: Maximum plasma concentration (Cmax) of ACT-777991 | Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered |
| All cohorts: Time to reach Cmax (tmax) of ACT-777991 | Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered |
| All cohorts: Terminal half-life (t1/2) of ACT-777991 | Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered |
| Part A (SAD): Absolute bioavailability of ACT-777991 | Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered |
| Part B (MAD): Excretion of radioactivity in urine and feces | Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration) |
| Part B (MAD): AUC during a dosing interval (AUCĪ) following the first and the last dose of ACT-777991. | Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered |
| Part A (SAD): Food effect evaluation only: AUC0-inf of ACT-777991 under fed conditions | Blood samples will be collected at predefined time points from Day 1 to Day 4. |
| Part A (SAD): Food effect evaluation only: Cmax of ACT-777991 under fed conditions | Blood samples will be collected at predefined time points from Day 1 to Day 4. |
| Part A (SAD): Food effect evaluation only: tmax of ACT-777991 under fed conditions | Blood samples will be collected at predefined time points from Day 1 to Day 4. |
| Part A (SAD): Food effect evaluation only: t1/2 of ACT 777991 under fed conditions | Blood samples will be collected at predefined time points from Day 1 to Day 4. |
| ID | Term |
|---|---|
| D064346 | Sagittal Abdominal Diameter |
| C110804 | mycophenolic adenine dinucleotide |
| ID | Term |
|---|---|
| D049628 | Body Size |
| D001837 | Body Weights and Measures |
| D001824 | Body Constitution |
| D010808 | Physical Examination |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D000886 | Anthropometry |
| D008919 | Investigative Techniques |
| D010829 | Physiological Phenomena |
Not provided
Not provided